Diagnostic Potential of Metabolomic and Proteomic Biomarkers in Cardiology—A Narrative Review
Authors:
- Lazzat ZhussupbekovaLZLazzat Zhussupbekova
- Dinara NurkinaDinara Nurkina
- Gyulnar ZhussupovaGZGyulnar Zhussupova
- Aliya SmagulovaASAliya Smagulova
- Venera RakhmetovaVRVenera Rakhmetova
- Elmira AkhmedyarovaEAElmira Akhmedyarova
- Aisha DarybayevaADAisha Darybayeva
- Klara KurmangaliyevaKKKlara Kurmangaliyeva
- Ilya KukesIKIlya Kukes
Open Access
- 23 January 2026
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 14 (2) , 257
Abstract
Cardiovascular disease is a major cause of death worldwide and a global socio-economic problem. To date, there are numerous studies focused on finding new biomarkers of cardiovascular diseases. High-technological methods such as mass spectrometry (MS), high-performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR) spectroscopy enable us to record thousands of metabolites of organs and tissues. Studying organisms at a molecular level contributes to an in-depth understanding of preclinical conditions of various diseases. Metabolomics reflects the dynamics of metabolism distribution, including environmental influences, allowing us to create a metabolic profile of the patient. The aim of this review was to analyze current data on metabolomic and proteomic biomarkers in the diagnosis of cardiovascular diseases. The search databases were used to select studies on the potential clinical and diagnostic application of proteomic and metabolomic markers in cardiology. The selected sources were subjected to qualitative and thematic analysis. All biomarkers were grouped according to the pathophysiological process (inflammation, blood coagulation and lipid metabolism disorders, myocardial necrosis, etc.). The association of changes in metabolomic and proteomic profiles with the activation of pathogenic processes in the cardiovascular system was demonstrated. The use of these multivariate markers, individually or in combination, will increase the accuracy of early diagnosis and the effectiveness of treatment. This article also highlights the limitations of the method and possible ways to solve them.Keywords
This publication has 142 references indexed in Scilit:
- Circulating Biomarkers in the Detection of Cardiovascular Toxicity2025
- Retinol binding protein 4 and type 2 diabetes: from insulin resistance to pancreatic β-cell functionEndocrine, 2024
- Diagnostic Value of PICP and PIIINP in Myocardial Fibrosis: A Systematic Review and Meta‐analysisClinical Cardiology, 2022
- Lower levels of vWF are associated with lower risk of cardiovascular diseaseResearch and Practice in Thrombosis and Haemostasis, 2022
- Serum VCAM ‐1 and ICAM ‐1 measurement assists for MACE risk estimation in ST ‐segment elevation myocardial infarction patientsJournal of Clinical Laboratory Analysis, 2022
- Copeptin plus troponin in the rapid rule out of acute myocardial infarction and prognostic value on post-myocardial infarction outcomes: a systematic review and diagnostic accuracy studyHeart and Vessels, 2022
- Elevated serum endothelin-1 is an independent predictor of coronary microvascular dysfunction in non-obstructive territories in patients with coronary artery diseaseHeart and Vessels, 2021
- The role of interferon-γ in cardiovascular disease: an updateInflammation Research, 2020
- Adrenomedullin in Heart Failure: Pathophysiology and Therapeutic ApplicationEuropean Journal of Heart Failure, 2018
- Machine Learning in Untargeted Metabolomics Experiments2018